These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35459718)

  • 1. Use of lipid-lowering therapy after ischaemic stroke and expected benefit from intensification of treatment.
    Gynnild MN; Hageman SHJ; Spigset O; Lydersen S; Saltvedt I; Dorresteijn JAN; Visseren FLJ; Ellekjær H
    Open Heart; 2022 Apr; 9(1):. PubMed ID: 35459718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease.
    Kovach CP; Mesenbring EC; Gupta P; Glorioso TJ; Ho PM; Waldo SW; Schwartz GG
    JAMA Netw Open; 2023 Aug; 6(8):e2329066. PubMed ID: 37638630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID).
    Shah NN; Ghazi L; Yamamoto Y; Martin M; Simonov M; Riello RJ; Faridi KF; Ahmad T; Wilson FP; Desai NR
    Am Heart J; 2022 Nov; 253():76-85. PubMed ID: 35841944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suboptimal lipid management before and after ischaemic stroke and TIA-the North Dublin Population Stroke Study.
    Ní Chróinín D; Ní Chróinín C; Akijian L; Callaly EL; Hannon N; Kelly L; Marnane M; Merwick Á; Sheehan Ó; Horgan G; Duggan J; Kyne L; Dolan E; Murphy S; Williams D; Kelly PJ
    Ir J Med Sci; 2018 Aug; 187(3):739-746. PubMed ID: 29368282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
    Burger PM; Dorresteijn JAN; Fiolet ATL; Koudstaal S; Eikelboom JW; Nidorf SM; Thompson PL; Cornel JH; Budgeon CA; Westendorp ICD; Beelen DPW; Martens FMAC; Steg PG; Asselbergs FW; Cramer MJ; Teraa M; Bhatt DL; Visseren FLJ; Mosterd A; ; ;
    Eur J Prev Cardiol; 2023 Dec; 30(18):1950-1962. PubMed ID: 37409348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid management in ischaemic stroke or transient ischaemic attack in China: result from China National Stroke Registry III.
    Xu YY; Chen WQ; Wang MX; Pan YS; Li ZX; Liu LP; Zhao XQ; Wang YL; Li H; Wang YJ; Meng X;
    BMJ Open; 2023 Mar; 13(3):e069465. PubMed ID: 36889830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Sjölander A; Carrero JJ
    J Am Heart Assoc; 2022 Jul; 11(14):e025813. PubMed ID: 35861825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C.
    Katzmann JL; Sorio-Vilela F; Dornstauder E; Fraas U; Smieszek T; Zappacosta S; Laufs U
    Clin Res Cardiol; 2022 Mar; 111(3):243-252. PubMed ID: 32949286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
    Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
    Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study.
    Ersbøll AK; Kristensen MS; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Lytken Larsen M; Green A
    PLoS One; 2023; 18(5):e0286376. PubMed ID: 37256879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study.
    Ur E; Langer A; Rabkin SW; Calciu CD; Leiter LA;
    Can J Cardiol; 2010 Feb; 26(2):80-6. PubMed ID: 20151053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.
    Kaasenbrood L; Ray KK; Boekholdt SM; Smulders YM; LaRosa JC; Kastelein JJP; van der Graaf Y; Dorresteijn JAN; Visseren FLJ
    Heart; 2018 Oct; 104(20):1699-1705. PubMed ID: 29622600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.
    Rollefstad S; Ikdahl E; Hisdal J; Kvien TK; Pedersen TR; Holme I; Semb AG
    Ann Rheum Dis; 2015 Aug; 74(8):1544-50. PubMed ID: 24699940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Carrero JJ
    Am Heart J; 2022 Sep; 251():78-90. PubMed ID: 35654163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.